Last reviewed · How we verify
bimatoprost Formulation C
At a glance
| Generic name | bimatoprost Formulation C |
|---|---|
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia (PHASE2)
- Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss (PHASE2)
- Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bimatoprost Formulation C CI brief — competitive landscape report
- bimatoprost Formulation C updates RSS · CI watch RSS
- Allergan portfolio CI